Key facts
- It has raised $2.8M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Amphora Capital China.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for AbMax Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for AbMax Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AbMax Biotechnology
Developer of a one-stop antibody and kit development designed to advance biotechnology research and applications. The company offers state-of-the-art antibody humanization technologies and vaccine-specific antibody solutions, enabling researchers and vaccine developers to achieve precise testing and enhanced vaccine quality.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2006
- Employees
- 36
- Website
- antibodychina.com/
- Ownership
- Privately Held (backing)
AbMax Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AbMax Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AbMax Biotechnology in its N-PORT filings yet. We sweep new filings monthly.